These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24964702)

  • 41. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A model-based study to estimate the health and economic impact of health technology assessment in Thailand.
    Kingkaew P; Budtarad N; Khuntha S; Barlow E; Morton A; Isaranuwatchai W; Teerawattananon Y; Painter C
    Int J Technol Assess Health Care; 2022 May; 38(1):e45. PubMed ID: 35506420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Standard cost lists for health economic evaluation in Thailand.
    Riewpaiboon A
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S127-34. PubMed ID: 24964710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A difficult balancing act: policy actors' perspectives on using economic evaluation to inform health-care coverage decisions under the Universal Health Insurance Coverage scheme in Thailand.
    Teerawattananon Y; Russell S
    Value Health; 2008 Mar; 11 Suppl 1():S52-60. PubMed ID: 18387068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement of clinical-effect: utility.
    Sakthong P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S43-52. PubMed ID: 19253487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Handling time in economic evaluation studies.
    Permsuwan U; Guntawongwan K; Buddhawongsa P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S53-8. PubMed ID: 19255986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The need for guidelines and the use of economic evidence in decision-making in Thailand: lessons learnt from the development of the national list of essential drugs.
    Wibulpolprasert S;
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S1-3. PubMed ID: 19255984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.
    McCarron CE; Pullenayegum EM; Marshall DA; Goeree R; Tarride JE
    Int J Technol Assess Health Care; 2009 Oct; 25(4):546-54. PubMed ID: 19845985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health technology assessment in Poland and Scotland: comparison of process and decisions.
    Kolasa K; Wasiak R
    Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
    Frederix GW; Haji Ali Afzali H; Dasbach EJ; Ward RL
    Pharmacoeconomics; 2015 Aug; 33(8):777-81. PubMed ID: 25827099
    [No Abstract]   [Full Text] [Related]  

  • 52. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.
    Philips Z; Bojke L; Sculpher M; Claxton K; Golder S
    Pharmacoeconomics; 2006; 24(4):355-71. PubMed ID: 16605282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Development of the Guide to Economic Analysis and Research (GEAR) Online Resource for Low- and Middle-Income Countries' Health Economics Practitioners: A Commentary.
    Adeagbo CU; Rattanavipapong W; Guinness L; Teerawattananon Y
    Value Health; 2018 May; 21(5):569-572. PubMed ID: 29753354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic data transferability for HTA: are we there yet?
    Manca A
    Value Health; 2009 Jun; 12(4):407. PubMed ID: 19900247
    [No Abstract]   [Full Text] [Related]  

  • 55. Belgian guidelines for economic evaluations: second edition.
    Thiry N; Neyt M; Van De Sande S; Cleemput I
    Int J Technol Assess Health Care; 2014 Dec; 30(6):601-7. PubMed ID: 25816826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Model Structuring for Economic Evaluations of New Health Technologies.
    Haji Ali Afzali H; Bojke L; Karnon J
    Pharmacoeconomics; 2018 Nov; 36(11):1309-1319. PubMed ID: 30030816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.
    Mathes T; Jacobs E; Morfeld JC; Pieper D
    BMC Health Serv Res; 2013 Sep; 13():371. PubMed ID: 24079858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health technology assessment in developing the National List of Essential Medicines in Thailand.
    Thamlikitkul V
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S3. PubMed ID: 24964692
    [No Abstract]   [Full Text] [Related]  

  • 60. Oncology from an HTA and Health Economic Perspective.
    Francois C; Zhou J; Pochopien M; Achour L; Toumi M
    Recent Results Cancer Res; 2019; 213():25-38. PubMed ID: 30543005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.